Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03085888 · ClinicalTrials.gov registry record
The STRIVE Study: Development of a Blood Test for Early Detection of Multiple Cancer Types
A clinical trial, sponsored by GRAIL.
- Completed
- Registry status
- 99,481
- Enrollment target
NCT03085888 is a clinical trial that has completed, run by GRAIL. The registered enrollment target is 99,481 participants.
The verdict
NCT03085888 has completed, sponsored by GRAIL.
- COMPLETED
- Registry status
- 99,481 participants
- Enrollment target
Study Summary
GRAIL is using high-intensity sequencing of circulating cell-free nucleic acids (cfNAs) to develop blood tests to detect cancer early. The purpose of this study is to validate the ability of the pre-specified GRAIL Test to detect breast cancer and other invasive cancers, including hematologic malignancies, that will occur within one year of the first study blood draw.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 99,481 participants |
| Start Date | 2017-02-28 |
| Est. Completion | 2024-04-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03085888
The ClinicalTrials.gov registry entry for NCT03085888 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 99,481 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GRAIL, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT03085888 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03085888 about?
NCT03085888 is a clinical study titled "The STRIVE Study: Development of a Blood Test for Early Detection of Multiple Cancer Types". GRAIL is using high-intensity sequencing of circulating cell-free nucleic acids (cfNAs) to develop blood tests to detect cancer early. The purpose of this study is to validate the ability of the pre-specified GRAIL Test to detect breast cancer and other invasive cancers, including hematologic malign...
What is the current status of trial NCT03085888?
This trial is currently completed. The enrollment target is 99,481 participants. The study started on 2017-02-28. Estimated completion is 2024-04-01.
Who is sponsoring clinical trial NCT03085888?
This trial is sponsored by GRAIL, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.